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Congenital Dyserythropoietic Anemia type II is an autosomal recessive disorder characterized by unique
abnormalities in the differentiation of cells of the erythroid lineage. The vast majority of CDA II cases result
from mutations in the SEC23B gene. To date, 53 different causative mutations have been reported in 86
unrelated cases (from the CDA II European Registry), 47 of them Italian. We have now identiﬁed SEC23B
mutations in 23 additional patients, 17 Italians and 6 non-Italian Europeans. The relative allelic frequency of
the mutations was then reassessed in a total of 64 Italian and 45 non-Italian unrelated patients. Two muta-
tions, E109K and R14W, account for over one-half of the cases of CDA II in Italy. Whereas the relative fre-
quency of E109K is similar in Italy and in the rest of Europe (and is also prevalent in Moroccan Jews), the
relative frequency of R14W is signiﬁcantly higher in Italy (26.3% vs. 10.7%). By haplotype analysis we dem-
onstrated that both are founder mutations in the Italian population. By using the DMLE1 program our
estimate for the age of the E109K mutation in Italian population is 2,200 years; whereas for the R14W
mutation it is 3,000 years. We hypothesize that E109K may have originated in the Middle East and may
have spread in the heyday of the Roman Empire. Instead, R14W may have originated in Southern Italy. The
relatively high frequency of the R14W mutation may account for the known increased prevalence of CDA II
in Italy. Am. J. Hematol. 86:727–732, 2011. V V C 2011 Wiley-Liss, Inc.
Introduction
Congenital dyserythropoietic anemia (CDA) was ﬁrst
described in 1968 as a condition characterized by a para-
doxical association of anemia and reticulocytopenia with
erythroid hyperplasia in the bone marrow [1,2]. It soon
became clear that the condition was heterogeneous, and
three forms became well known [1], with Type II being the
most frequent. The prevalence of CDAs in Europe has
been recently assessed. The combined prevalence of CDA
I and CDA II (based on all cases reported in the last 42
years) has the highest value in Italy (2.49/million). CDA II
(367 cases) is relatively more frequent than CDA I (122
cases), with an overall ratio of approximately 3.0 [3].
CDA II is an autosomal recessive condition presenting
with moderate to severe normocytic or microcytic anemia,
with a normal or insufﬁciently increased reticulocyte count,
chronic or intermittent jaundice, splenomegaly [4]. Bone
marrow of CDA II patients is characterized by presence of
bi-nucleated or multinucleated normoblasts. In addition,
upon electron microscopy, vesicles of endoplasmic reticu-
lum appear to be running beneath the plasma membrane
[5]. Furthermore a number of abnormalities affecting glyco-
sylation and/or levels of erythrocyte glycoconjugates were
observed. Hypoglycosylation of erythrocyte anion
exchanger 1 represents a key for the diagnosis [6] and sug-
gests a defect in vesicles trafﬁcking.
After the demonstration that 28 unrelated cases of CDA II
were associated with mutations in the SEC23B gene [7], a
total of 53 different causative mutations have been identiﬁed
in 86 unrelated cases, mostly of European origin [7–11]. The
SEC23B gene encodes the SEC23B component of the
COPII complex, involved in the anterograde transport of cor-
rectly folded protein from the endoplasmic reticulum towards
the Golgi [12]. Although most of the mutations found in
SEC23B gene appear to result from independent events, 4
mutations (R14W, E109K, R497C, I318T) account for more
than 50% of mutant alleles, which is a help with respect to
molecular diagnosis [9,11]. In a recent paper, Amir and col-
leagues found that in Israel all patients diagnosed with CDA
II to date are of North-African descent, mainly Moroccan-
Jews, and they are all homozygotes for the E109K mutation.
Moreover, the authors have observed in these patients a
common haplotype, suggesting a founder mutation, esti-
mated to have taken place about 2,400 years ago [13].
Here, we report on 23 additional patients, 17 Italian, and 6
non-Italian Europeans, and we show that E109K and R14W
account for about 54% of all patients in Italy. By extensive
haplotype analysis we show that the recurrent SEC23B-
R14W mutation found in most of the Italian families with
CDA II is likely due to a founder effect, with the founder
mutation having occurred probably in Southern Italy. By con-
trast, E109K is more widespread within Europe.
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Subjects and relative allelic frequency assessment. To date, 86
unrelated european cases of CDA II due to 53 different causative
mutations have been described [7–11]. Among them, 47 unrelated
cases had Italian origin with 31 different mutations, 39 were non-Ital-
ian European (NIE) patients with 32 different mutations. Furthermore
we included 17 Italian and 6 NIE unrelated cases still unpublished,
with an overall count of 64 Italian and 45 NIE patients (Supporting
Information Table Is).
Haplotype analysis was carried out in 31 Italian CDA II patients
from 23 independent families and six NIE cases from four unrelated
families. Moreover, we conﬁrmed the E109K haplotype on three
Moroccan Jewish patients. We also enrolled 47 healthy subjects origi-
nated from Italy (Supporting Information Table IIs). Blood samples
were collected following approval by the local ethics committees. Writ-
ten consent was obtained from all patients in accordance with the
Declaration of Helsinki.
SEC23B sequencing. Genomic DNA was prepared from peripheral
blood using Wizard Genomic DNA puriﬁcation kit (Promega, Milano,
Italy). Mutational search, oligonucleotide primers design and direct
sequencing were performed as previously described [9]. SEC23B
sequence primers are available upon request (achille.iolascon@uni-
na.it). Nucleotide numbering reﬂects cDNA numbering with 11 corre-
sponding to the A of ATG translation initiation codon in the reference
sequence (Ensembl transcript ID: ENST00000377475).
Marker selection. Single nucleotide polymorphisms (SNPs) were
selected from the HapMap Project Home Page (http://hapmap.
ncbi.nlm.nih.gov/). By using the International HapMap Project phase II
[14] we downloaded a list of 9370 SNPs within a region of 1,685 kb
upstream, 2,656 kb downstream of the SEC23B gene. From this list, all
SNPs with a minor allele frequency (MAF) > 0.35 were chosen to iden-
tify the tag-SNPs, to avoid redundant typing of sets of variants that are
in complete linkage disequilibrium with each other [15].
By using Haploview software package [16], 12 tag-SNPs with a
threshold of r
2 > 0.8 were selected (rs241141, rs8121302, rs6111826,
rs761463, rs6136363, rs13039328, rs6045524, rs6132097, rs6045592,
rs742731, rs6105992, rs6045803) covering a region of about 1.2 Mb.
SNPs genotyping. SNPs genotyping was performed with direct
sequencing. All fragments were ampliﬁed from genomic DNA by PCR
in a 25 ll volume with Expand High Fidelity PCR System, following
manufacturer’s protocol (Roche, Germany). The oligonucleotide primers
were designed from the sequence downloaded from the NCBI dbSNP
Home Page (http://www.ncbi.nlm.nih.gov/projects/SNP/), by Primer3
program (Primer3 v. 0.4.0, freeware online) (Supporting Information Ta-
ble IIs). The PCR products were checked by DNA agarose gel electro-
phoresis. Direct sequencing was performed using the BigDye
1 Termi-
nator Cycle Sequencing Kit (Applied Biosystems, Branchberg, NJ) and
a 3730 DNA Analyzer (Applied Biosystems).
Haplotype analysis. For each SNP, the allele frequencies were
deﬁned, and testing for Hardy-Weinberg equilibrium was performed in a
control sample from the general population of Italy (Supporting Informa-
tion Table IIs). Haplotypes at the gene locus were deﬁned using the
modiﬁed estimation-maximization algorithm implemented in the Haplo-
view software package [16]. We included genotypes information of 47
Italian unrelated controls and 174 Caucasian controls (HapMap CEU),
downloaded from the HapMap Project home page. When we compared
the allele and genotype frequencies of HapMap CEU population with
those of 47 Italian healthy subjects, we did not ﬁnd any signiﬁcant dif-
ference (Supporting Information Table IIs).
Age of mutation analysis. DMLE1 version 2.3 developed by Reeve
and Rannala (http://dmle.org/) was used to estimate the age of both,
R14W and E109K mutations. This program was designed for high-reso-
lution mapping of a disease mutation and estimation of its age. The
method is based on the observed linkage disequilibrium between a dis-
ease mutation and linked markers in DNA samples of unrelated normal
individuals and affected patients. The program uses the Markov Chain
Monte Carlo algorithm to allow Bayesian estimation of the mutation
age based on the following parameters: the observed haplotypes (or
genotypes) in samples of unrelated normal or affected chromosomes,
map distances between markers, the position of the mutation relative
to the markers and the population growth rate, and an estimate for the
proportion of disease-bearing chromosomes [17]. We performed two
analyses: (i) age estimation of R14W haplotypes of 23 italian patients;
(ii) age estimation of E109K haplotypes of eight italian cases.
The population growth rate (r) was estimated by the equation,
accordingly to previously described method [18]: T1 5 T0e
(gr), in which
T1 is the estimated size of population today in Italy (58 million), T0 is
the estimated size of the ancestral population (2 million between the
5th and 3rd centuries BC), and g is the number of generations between
these 2 time points (g 5 64.4 considering 25 years for a generation).
Accordingly, population growth rate was estimated to be approximately
equal to 0.05. We used a proportion of population sampled of 0.0072
for E109K and 0.0045 for R14W cases, using a previously described
method [19].
Results
Sequencing analysis and frequency
of individual SEC23B mutations
We tested for mutations in the SEC23B 23 unpublished
unrelated cases (Supporting Information Table Is). The vast
majority of them had two mutations (in the homozygous or
compound heterozygous state), in accordance with the pat-
tern of autosomal recessive inheritance. Five patients
(F53P1, F62P1, F64P1, F65P1, F66P1) of the 23 studied
showed only one mutation in the heterozygous state (Sup-
porting Information Table Is). By combining the data with
those previously available we have a total of 64 subjects
from Italy and 45 NIE. Overall we found 31 different causa-
tive mutations in Italian patients. They included 14 mis-
sense, eight nonsense, four frameshift, four splice site muta-
tions, and only one amino acid deletion. The distribution of
different types of mutations is similar in NIE cases (19 mis-
sense, eight nonsense, three frameshift, two splicing).
In agreement with previous ﬁndings [9], the commonest
mutations in the Italian cases were the missense substitu-
tions E109K and R14W (28.0% and 26.3% respectively).
When comparing the relative frequencies of 10 mutations
(Fig. 1) present in both Italian and NIE cases, R14W stood
out as far more common in Italian CDA II patients than in
NIE (26.3% vs. 10.7%). By contrast, E109K had about the
same frequency in the two groups (28.0% in Italian patients
vs. 25.0% in NIE) (Fig. 1).
Haplotype analysis
In order to investigate the evolution of CDA II in Italy we
used the haplotype method in a case-control study [20], by
selecting SNP markers located near the commonest
SEC23B mutations, R14W and E109K. Speciﬁcally, we
examined 12 tag-SNP markers within 1.2 Mb within the
SEC23B gene locus (Fig. 2). All of 23 Italian R14W patients
from 16 independent families were heterozygous for this
mutation (Table I, Supporting Information Fig. 1s). Of these
R14W-patients, 47.2% shared a common haplotype
(CACACCGC), composed by 8 SNPs (rs761463, rs6136363,
rs13039328, rs6045524, rs6132097, rs6045592, rs742731,
rs6105992) spanning a 667.9 kb region upstream and down-
stream the mutation (Table I). The same haplotype was
found only in a small percentage of Italian controls (4%) and
in HapMap CEU population (1%).
For the E109K mutation we had 14 homozygotes and 2
heterozygotes (Table II, Supporting Information Fig. 2s).
Haplotype analysis showed that E109K-patients carried a
common haplotype (CATAGT, 96.4%) composed by 6
SNPs (rs13039328, rs6045524, rs6132097, rs6045592,
rs742731, rs6105992) spanning a 441.1 kb region within
SEC23B upstream and downstream the mutation (Table II).
The same haplotype was found only in a small percentage
in Italian controls (5%) and in HapMap CEU population
(3%). The same haplotype analysis in 3 Moroccan Jewish
patients, homozygous for the E109K mutation, showed a
similar chromosomal background, except for one marker
(rs6105992) not conserved in the haplotype of the Moroc-
can Jewish patients (Supporting Information Table IIIs).
Time of origin of the R14W and E109K mutations
We used the DMLE1 program to obtain a Bayesian
estimate of how old these mutations might be. On the basis
of 23 R14W Italian patients we obtained a peak at 124
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fore, if the generation span is considered to be 25 years
[21], this mutation would date back approximately to 3,000
years ago.
For E109K the same analysis revealed an estimated age
of 91 generations (95% credible set, 63–156), calculated
using haplotypes frequencies of the 8 Italian patients (Fig.
3B). Thus, this mutation would date back approximately to
2,200 years ago.
Discussion
CDA II results from mutations that cause loss of function
of the SEC23B gene. As for other autosomal recessive
conditions, it is not surprising that many different mutations
are found in patients, because there are many amino acid
changes that can produce loss of function. To date we
know 53 different mutations in SEC23B causing CDA II [7–
11]. Here, we expanded the cohort of CDA II patients of
European Registry (109 CDA II cases) including 17 Italian
and 6 NIE unrelated cases still unpublished.
In this study, we compared the relative allelic frequency
of SEC23B mutations in two cohorts of cases, 64 Italian
and 45 NIE cases. We show (Fig. 1) that, whereas the ma-
jority of SEC23B mutations are found only occasionally, two
mutations, R14W and E109K are relatively common in both
cohorts, substantially conﬁrming our previous data [9,11].
Nevertheless, R14W variant showed a higher recurrence in
Italian CDA II patients when compared to NIE patients
(26.3% vs 10.7%), while E109K substitution showed almost
the same allelic frequency between both groups (28.0% in
Italian and 25.0% in NIE). In general, there are two possi-
ble explanations. Either (a) the mutation has been positively
selected, or (b) it has spread by genetic drift: i.e., it results
from a so-called founder effect. It is difﬁcult to imagine that
mutations that give no known phenotype in the heterozy-
gous state, and cause a disease in the homozygous state,
can be positively selected; therefore in principle (b) seems
more likely in this case. A founder effect implies that identi-
cal mutant genes we see today have a single ancestral ori-
gin; and the spread of the mutant gene may have been
greatly favored if at some stage a small population in which
the gene was present has undergone rapid expansion.
Haplotype analysis can provide minimum estimates for the
time of origin of a founder mutation; more exactly, of the
Figure 2. SNP markers localization upstream and downstream E109K and R14W mutations. The chromosomal region containing the SEC23B gene is shown. Arrows
indicate the distances of SNP markers from the location of the SEC23B mutation. Names of SNP markers are shown on the bars, whose height is shown to scale with
the MAF. Distances in kb of SNP markers from both mutations, E109K and R14W, are highlighted in gray and black, respectively. [Color ﬁgure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
Figure 1. Allelic frequency of the mutations. The chart shows the results of the analysis performed on 10 mutations (E109K, R14W, R701C, R497C, R217X, R79X,
A524V, R264X, R339X, R535X) shared between two cohorts. The allelic frequency has been assessed on 118 alleles from Italian cases and 84 from those not Italian.
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research articletime when the mutation has spread, presumably because
of population bottleneck was followed by expansion.
As we already stated, E109K and R14W mutations
occurred in codons containing a complete or overlapping
CpG dinucleotide (gccGAAttg and gaaCGGgat, respec-
tively), a ‘‘hot spot’’ for mutations [9]. Nevertheless, our
analysis strongly supports the notion that E109K and
R14W are both examples of founder effects. E109K is par-
ticularly common in Moroccan-Jewish patients with CDA II
[13], but it is also common in Italy and in other parts of
Europe. We have now found that three Moroccan-Jewish
E109K-patients have a chromosomal background similar to
those found in Italian and European patients. Considering
the wide conﬁdence limits of any estimate of the origin of a
mutation, our result of 2,200 years are not far from the esti-
mate of 2,400 years given by Amir [13]. Alternatively, these
different estimates might reﬂect several successive waves
of expansion. We could hypothesize that the mutation was
born in the Middle Est 2,400 years and arrived in European
regions approximately at the time of Caesar Augustus
when Roman Empire had the maximum expansion: thus,
this mutation may then have spread throughout the Medi-
terranean area and perhaps elsewhere in the Roman
Empire (Fig. 4).
For the most frequent mutation in Italian CDA II patients,
R14W, we found a common haplotype (CACACCGC) in
47% of 23 heterozygote Italian patients: of note, this haplo-
type is different from those observed in E109K-patients.
Figure 4. Dissemination of the E109K mutation in the Mediterranean area. The map shows the empire’s greatest and largest territory in the year of 116 AD, around the
time of Caesar Augustus (63 BC–14 AD) [The map is modiﬁed from a picture covered by Copyright AskRickToday.Com]. The dashed black arrows indicate the hypotheti-
cal migratory movements that led to the spread of the mutation in the Mediterranean area. Dots indicate the geographical areas in which the E109K mutation ﬁrst
occurred. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 3. R14W and E109K age estimation. Age estimation of SEC23B R14W (A) and E109K (B) mutations. The posterior probability plots of the mutations age (in
generations), as estimated by the software DMLE12.3. The analyses were performed according to growth rate (r) of Italian populations. The vertical lines represent the
average age values that had the highest probability (peak). The average 95% credible set (CS) of values for each posterior density is shown.
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mately 3000 years ago, at the time when much of Southern
Italy was a Greek colony, the Magna Graecia. On the basis
of the geographic distribution of CDA II, showing a concen-
tration of this disease in Southern Italy and in Mediterranean
countries, we had previously suggested that a particular CDA
II mutation arose or was introduced in Southern Italy, from
where it might have spread over the rest of the country [4].
Our new data fully support this suggestion: of 16 unrelated
R14W-patients here analyzed, 13 (81%) were from Central
and Southern Italy. In a recent review of epidemiologic data it
was conﬁrmed that in Italy the prevalence of CDA II is higher
than in other European countries, 2.49 cases per million
[3]. If we subtract from this ﬁgure the contribution of patients
with the R14W mutation, we ﬁnd that the prevalence in Italy
would fall in line with the rest of Europe: this means that the
epidemiological anomaly of CDA II in Italy is accounted by
this particular founder effect.
In this study, we characterized the allelic distribution of
SEC23B gene mutations found in CDA II Italian patients,
compared to those found in not Italian European cases. We
demonstrated that the most frequent amino acid substitu-
tions, R14W and E109K, are founder mutations in the Ital-
ian population; but, the ﬁrst one may have originated in
Southern Italy (3,000 years ago), while the latter is more
widespread within Europe.
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